Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3311499 | 0.99 | RAB9A (0.54) | RAB9AMAPTKMT2AMEN1KDM4E | |
| SCHEMBL3311503 | 0.86 | RAB9A (0.55) | RAB9AMAPTKMT2AMEN1KDM4E | |
| SCHEMBL14514815 | 0.83 | L3MBTL1 (0.43) | RAB9AKMT2AMEN1KDM4ESMN1; SMN2 | |
| SCHEMBL12035866 | 0.83 | RAB9A (0.59) | RAB9AMAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL3303647 | 0.82 | L3MBTL1 (0.42) | RAB9AKMT2AMEN1KDM4ESMN1; SMN2 | |
| SCHEMBL31532609 | 0.79 | RAB9A (0.58) | RAB9AMAPTKMT2AMEN1KDM4E | |
| SCHEMBL838607 | 0.77 | RAB9A (0.68) | RAB9AMAPTKMT2AMEN1KDM4E | |
| SCHEMBL1723416 | 0.77 | RAB9A (0.68) | RAB9AMAPTKMT2AMEN1KDM4E | |
| SCHEMBL19116525 | 0.76 | RAB9A (0.62) | RAB9AMAPTKMT2AMEN1KDM4E | |
| SCHEMBL17450654 | 0.75 | RAB9A (0.66) | RAB9AMAPTKMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129371-A1 | Novel ethylenediamine derivatives | C1R, C9, C1S | RAB9A 3871/4885MAPT 4390/4885KMT2A 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.